Initial clinical results have demonstrated good tolerability, significant inhibition of SYK and JAK, and greater than 50% target tumor reductions in patients with CLL and NHL (Flinn I, et al. 2015 ASCO annual meeting Abstract #8531). The gene discussed is SYK; the disease is neoplasm.